- Home
- JSPR vs ADCT Comparison
JSPR vs ADCT Comparison
Compare JSPR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ADCT
- Stock Information
- Founded
- JSPR 2018
- ADCT 2011
- Country
- JSPR United States
- ADCT Switzerland
- Employees
- JSPR N/A
- ADCT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ADCT Health Care
- Exchange
- JSPR Nasdaq
- ADCT Nasdaq
- Market Cap
- JSPR 323.0M
- ADCT 224.3M
- IPO Year
- JSPR N/A
- ADCT 2020
- Fundamental
- Price
- JSPR $22.48
- ADCT $2.97
- Analyst Decision
- JSPR Strong Buy
- ADCT Strong Buy
- Analyst Count
- JSPR 11
- ADCT 5
- Target Price
- JSPR $73.38
- ADCT $7.33
- AVG Volume (30 Days)
- JSPR 211.1K
- ADCT 897.3K
- Earning Date
- JSPR 11-07-2024
- ADCT 11-07-2024
- Dividend Yield
- JSPR N/A
- ADCT N/A
- EPS Growth
- JSPR N/A
- ADCT N/A
- EPS
- JSPR N/A
- ADCT N/A
- Revenue
- JSPR N/A
- ADCT $70,717,000.00
- Revenue This Year
- JSPR N/A
- ADCT $6.38
- Revenue Next Year
- JSPR N/A
- ADCT $11.73
- P/E Ratio
- JSPR N/A
- ADCT N/A
- Revenue Growth
- JSPR N/A
- ADCT N/A
- 52 Week Low
- JSPR $4.00
- ADCT $0.94
- 52 Week High
- JSPR $31.01
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- JSPR 52.21
- ADCT 41.63
- Support Level
- JSPR $20.73
- ADCT $1.80
- Resistance Level
- JSPR $26.05
- ADCT $2.38
- Average True Range (ATR)
- JSPR 1.60
- ADCT 0.20
- MACD
- JSPR -0.10
- ADCT 0.00
- Stochastic Oscillator
- JSPR 48.48
- ADCT 52.27
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.